Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01022970 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 5
- Study locations
NCT01022970 is a Phase 2 study of Eosinophilic Esophagitis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 25 participants, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01022970, a Phase 2 study of Eosinophilic Esophagitis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to investigate the effects of a 12 week course of intravenous QAX576 6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients by 75% or greater when compared with baseline.
Conditions Studied
Interventions
- DRUG QAX576 placebo
- DRUG QAX576
Study Locations (5)
California
- Stanford Medical Center and Lucile Packard Children's Hospital - Stanford
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Minnesota
- Mayo Clinic - Minneota
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Virginia
- Oral Alpan, 6210 Old Keene Mill Court, - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01022970
The ClinicalTrials.gov registry entry for NCT01022970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (97% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which QAX576 placebo is the first listed.
NCT01022970 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01022970 about?
NCT01022970 is a clinical study titled "Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis". This study is designed to investigate the effects of a 12 week course of intravenous QAX576 6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients by 75% or greater when compared with baseline.
What is the current status of trial NCT01022970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2009-11.
What conditions does trial NCT01022970 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT01022970?
The interventions under investigation include: QAX576 placebo (DRUG), QAX576 (DRUG).
Who is sponsoring clinical trial NCT01022970?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01022970 being conducted?
This trial has 5 study locations across California, Illinois, Minnesota, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.